217 related articles for article (PubMed ID: 26907632)
1. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
2. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloidosis.
Merlini G; Comenzo RL; Seldin DC; Wechalekar A; Gertz MA
Expert Rev Hematol; 2014 Feb; 7(1):143-56. PubMed ID: 24350907
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
5. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
6. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
7. How we treat systemic light-chain amyloidosis.
Chaulagain CP; Comenzo RL
Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
[TBL] [Abstract][Full Text] [Related]
8. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies.
Dasari S; Theis JD; Vrana JA; Meureta OM; Quint PS; Muppa P; Zenka RM; Tschumper RC; Jelinek DF; Davila JI; Sarangi V; Kurtin PJ; Dogan A
J Proteome Res; 2015 Apr; 14(4):1957-67. PubMed ID: 25734799
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
[TBL] [Abstract][Full Text] [Related]
11. Use of novel therapies in the treatment of light chain amyloidosis.
Varga C; Titus SE; Toskic D; Comenzo RL
Blood Rev; 2019 Sep; 37():100581. PubMed ID: 31167719
[TBL] [Abstract][Full Text] [Related]
12. Systemic immunoglobulin light-chain amyloidosis.
Comenzo RL
Clin Lymphoma Myeloma; 2006 Nov; 7(3):182-5. PubMed ID: 17229332
[TBL] [Abstract][Full Text] [Related]
13. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
[TBL] [Abstract][Full Text] [Related]
14. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
15. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
[TBL] [Abstract][Full Text] [Related]
16. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
17. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Oliva L; Orfanelli U; Resnati M; Raimondi A; Orsi A; Milan E; Palladini G; Milani P; Cerruti F; Cascio P; Casarini S; Rognoni P; Touvier T; Marcatti M; Ciceri F; Mangiacavalli S; Corso A; Merlini G; Cenci S
Blood; 2017 Apr; 129(15):2132-2142. PubMed ID: 28130214
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
[TBL] [Abstract][Full Text] [Related]
20. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
Cohen AD; Comenzo RL
Hematology Am Soc Hematol Educ Program; 2010; 2010():287-94. PubMed ID: 21239808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]